Neurotech: what are the biggest challenges now?

Why is neurotechnology advancing so quickly but still reaching so few patients?

Neurotechnology is making real medical progress, but getting brain-interface devices into everyday clinical use remains surprisingly difficult.

A review published in Nature Reviews Bioengineering in September 2024 identified just 67 people implanted with experimental brain-computer interfaces (BCIs) across 28 clinical trials conducted between 1998 and 2023. After 25 years of research, the average trial had involved only 2.4 participants.

The picture is changing. Neuralink has demonstrated computer control through implanted electrodes, Synchron is expanding clinical testing of its endovascular interface, and Precision Neuroscience announced in September 2026 that its technology had been used in more than 100 patient procedures across 18 medical institutions. Precision also raised $250 million, bringing its total funding to approximately $430 million.

Meanwhile, the medical demand is enormous. A Global Burden of Disease study published in The Lancet Neurology estimated that 3.4 billion people experienced conditions affecting the nervous system in 2021. Only a small fraction have conditions that existing brain interfaces could realistically treat.

We also need to distinguish experimental BCIs from established neurotechnology. Deep brain stimulation already treats selected neurological disorders, while consumer EEG devices can record brain activity without surgery. Each faces different problems.

The challenge now is getting more patients access to treatments that work reliably outside carefully controlled research settings.

Are brain implants still too dangerous for widespread use?

Brain implants are currently too invasive for healthy consumers, although their risks can be justified for patients with severe neurological disabilities.

Neuralink's first participant, Noland Arbaugh, received an implant in January 2024. Within weeks, a substantial proportion of the electrode threads had retracted, reducing the number of usable recording channels. Reporting by The Wall Street Journal indicated that approximately 85% of the threads became displaced. Neuralink subsequently recovered much of the lost functionality through software changes.

Synchron approaches the problem differently. Its Stentrode is delivered through blood vessels rather than by inserting penetrating electrodes into the brain. In the six-participant COMMAND study, the company reported no brain- or blood-vessel-related serious adverse events over 12 months.

Precision Neuroscience places a thin electrode array on the brain's surface, avoiding the tissue penetration required by intracortical electrodes. Its growing clinical experience shows how companies are exploring less invasive ways to record neural activity.

These approaches reduce different risks, but none eliminates concerns about infection, inflammation, device movement, long-term durability, or future removal.

For someone unable to communicate or move independently, brain surgery may be a reasonable trade-off. For someone hoping to type faster or improve concentration, the benefits are currently much harder to justify.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Why is keeping a brain implant working for years so difficult?

Long-term reliability remains one of the hardest problems in neurotechnology because electrodes must work inside a biological environment that changes over time.

Implanted electrodes can experience tissue reactions, mechanical movement, material degradation, and changes in nearby neural activity. Even when the hardware survives, the software interpreting those signals may need recalibration.

Neuralink's early thread-retraction problem illustrated the difficulty of keeping electrodes mechanically stable. Synchron's endovascular design reduces direct penetration of brain tissue, although it introduces different constraints related to blood vessels and electrode positioning.

Long-running academic research provides some reassurance. The Nature Reviews Bioengineering review reported an average participation duration of 40.2 months among people still active in implanted-BCI trials. However, participation duration does not necessarily indicate uninterrupted device performance.

Paradromics has also reported multiyear stability from its neural-recording technology, although its long-duration evidence has largely come from preclinical work. Animal recordings cannot establish equivalent durability in human patients.

For patients, the important question is straightforward: will the implant continue working without frequent repairs, recalibration, or additional surgery?

That remains insufficiently demonstrated across the newest commercial devices.

Can AI finally make brain-computer interfaces accurate enough?

AI has dramatically improved brain-computer interfaces, particularly for restoring communication, but decoding accuracy still depends heavily on the quality and stability of recorded signals.

A Stanford-led study published in Nature in 2023 decoded attempted speech at 62 words per minute from a participant with ALS. The system achieved a 9.1% word error rate with a 50-word vocabulary, compared with 23.8% when tested against a vocabulary of 125,000 words.

That difference is revealing. Recognizing words from a limited selection is considerably easier than interpreting unrestricted language.

Research published in the New England Journal of Medicine in 2024 demonstrated another important advance. A speech BCI achieved approximately 97.5% word accuracy after calibration in a participant with ALS, showing that high-quality communication can be sustained over months in an experimental setting.

Researchers have since demonstrated near-real-time speech synthesis from neural activity, reducing the delays between a person's attempted speech and the computer's response.

AI helps by identifying complex patterns across neural recordings, and newer research is exploring models trained on much larger collections of brain data. Yet algorithms still struggle when signals change, electrode placement differs, or a new patient produces patterns that were poorly represented during training.

Impressive decoding accuracy is now possible. Getting that performance consistently across different patients, without extensive individual calibration, is a much harder test.

Can noninvasive brain interfaces compete with implanted devices?

Noninvasive brain-computer interfaces are becoming more attractive, but implanted systems still have a substantial advantage when detailed, fast neural recordings are essential.

Intracortical electrodes can capture activity close to individual neurons. Surface arrays record broader patterns without penetrating brain tissue. Endovascular devices measure activity from within nearby blood vessels, while external EEG systems avoid surgery but record signals weakened and distorted by the skull.

Ultrasound is now attracting more attention. Bridge Neurotech launched in October 2026 with $13.5 million in funding to develop a wearable ultrasound-based brain interface. Its approach uses measurements related to blood flow and AI models to infer neural activity. The company is exploring a route that could avoid surgical implantation.

The challenge is speed. Blood-flow changes develop more slowly than the electrical activity that drives neural communication, making fast control difficult without prediction.

For now, no noninvasive approach has demonstrated that it can match the full performance of high-bandwidth intracortical recording across demanding tasks.

Technology	Example	Main advantage	Biggest limitation
Intracortical electrodes	Neuralink N1	Detailed neural recordings	Penetrating brain surgery
Intracortical arrays	BrainGate	Extensive human research history	Surgical and maintenance demands
Cortical surface arrays	Precision Layer 7	Dense recordings without penetrating cortex	Limited access to deeper neural activity
Endovascular interface	Synchron Stentrode	Avoids open-brain electrode implantation	Recording depends on vascular anatomy
Scalp EEG	EMOTIV systems	Portable and noninvasive	Signal noise and lower spatial resolution
Functional ultrasound	Bridge Neurotech	Potential access to deeper activity without implants	Indirect signals and slower response
Optical monitoring	fNIRS research systems	Noninvasive blood-oxygenation measurement	Slow response and limited anatomical access

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Why are neurotech clinical trials still so small?

Brain-computer interface trials remain small because suitable patients are difficult to recruit, implantation requires specialist teams, and researchers need years of follow-up to understand safety.

The historical numbers are striking. The Nature Reviews Bioengineering review covered 28 implanted-BCI trials and 67 participants across approximately 25 years. The researchers also identified substantial underrepresentation of women.

More recent programs are expanding that base. Synchron's COMMAND study enrolled six participants, while its INTENT early-feasibility study began in 2026. Precision Neuroscience has moved much faster in terms of patients exposed to its technology, reporting more than 100 procedures by September 2026.

However, Precision's procedures often involve temporary recordings during neurosurgery. They provide useful evidence about recording quality and surgical handling but cannot establish the long-term safety of permanently implanted BCIs.

This distinction is frequently lost when companies announce patient milestones.

A study involving 100 short surgical procedures answers very different questions from one following 100 people living with permanent implants for several years.

The field needs both types of research, although long-term human evidence remains particularly scarce.

Are neurotech devices actually improving patients' lives?

Neurotechnology has already restored useful abilities in people with severe disabilities, but the evidence becomes thinner when we ask how much independence patients gain over years.

Neuralink participants have controlled computers, played games, and communicated using neural signals. Synchron's COMMAND study demonstrated computer control through motor intention in six participants. Academic speech-BCI research has enabled people with ALS to communicate using decoded attempted speech.

These achievements are meaningful, especially for patients who have lost conventional communication methods.

Still, a successful computer-control session tells us relatively little about how many hours patients can use the device independently, whether fatigue limits performance, or how much assistance caregivers must provide.

Established neurostimulation offers a useful comparison. Medtronic received FDA approval for adaptive deep brain stimulation in February 2025. The technology adjusts stimulation based on recorded brain activity rather than delivering only fixed settings.

In its ADAPT-PD research, Medtronic reported approximately 1.3 additional hours per day of symptom-controlled time in a relevant comparison. That's a benefit patients can recognize in daily life.

Communication BCIs need similarly practical measurements: successful conversations, independent computer use, reduced caregiver assistance, and reliable operation over months or years.

Could eye tracking and other simpler devices make brain implants unnecessary?

Simpler assistive technologies will remain the better choice for many patients because brain implants currently add substantial medical complexity.

Eye-tracking systems, switches, specialized communication software, and voice assistants already help people with movement or speech disabilities use computers.

For patients who retain reliable eye movement, those solutions may provide sufficient control without surgery. The situation changes when someone has severe paralysis, impaired eye movement, or difficulty using existing devices for extended periods.

The Stanford speech-BCI study achieved 62 words per minute in 2023, compared with 18 words per minute in an earlier handwriting-BCI demonstration. Both represented important improvements, although the experiments involved different tasks and participants.

Their performance cannot be translated into a universal advantage over eye tracking or other communication aids.

Neuralink and Synchron therefore have particularly compelling early applications among patients whose available control methods are inadequate.

Expanding beyond that group will be harder. Brain implants need to offer a substantial improvement in everyday function before their surgical and maintenance costs become worthwhile.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Is neurotech regulation moving fast enough?

Neurotechnology regulation is making progress, but permanently implanted communication systems still face a much longer approval journey than temporary recording devices or established neurostimulation treatments.

In March 2025, Precision Neuroscience received FDA 510(k) clearance for its Layer 7-T electrode array. The authorization covered specified recording, monitoring, and stimulation uses for up to 30 days. It did not authorize permanent brain-computer communication.

Medtronic's adaptive deep brain stimulation system received FDA approval a month earlier, building on an existing platform and decades of clinical experience with deep brain stimulation.

Neuralink and Synchron, meanwhile, are gathering clinical evidence under investigational pathways. Their devices must establish safety and effectiveness for the intended applications before routine commercial use becomes possible.

AI adds another difficulty. Neural-decoding software can improve through updates, but changes to medical algorithms require appropriate validation and control.

In August 2025, the FDA finalized guidance on predetermined change-control plans for AI-enabled medical devices, providing a framework for certain planned software modifications.

BCI developers have to prove that both the hardware and the evolving decoding system remain safe and reliable.

Who will pay for brain-computer interfaces?

Insurance reimbursement remains a major obstacle for implanted brain-computer interfaces because experimental demonstrations have not yet produced a widely established payment model.

The U.S. Government Accountability Office highlighted reimbursement uncertainty in its December 2024 assessment of BCI technology. It also warned about the support patients may need after clinical trials finish.

The costs extend beyond the implant. Patients may need surgery, rehabilitation, individual calibration, software maintenance, technical support, and eventual device replacement.

Existing deep brain stimulation has reimbursement pathways for qualifying patients and indications. Newer communication BCIs cannot automatically use those pathways simply because they also interact with the brain.

A company could obtain authorization for an effective device yet still struggle to find hospitals and insurers willing to pay for it.

Evidence of improved communication, independence, and reduced care needs could help support reimbursement decisions. However, the economic case will vary considerably between patients.

Until payment becomes predictable, commercial adoption is likely to remain concentrated in specialist medical centers and carefully selected cases.

Can brain-computer interfaces ever become affordable?

Implanted brain-computer interfaces could become considerably cheaper to deploy, but their total treatment cost is unlikely to resemble that of ordinary consumer electronics anytime soon.

Neuralink's robotic implantation strategy targets a procedure that would otherwise depend heavily on specialized surgical work. Synchron uses endovascular techniques already familiar to neurointerventional specialists, while Precision Neuroscience is pursuing applications that can fit into existing neurosurgical workflows.

Each strategy could reduce a different cost.

The hardware itself is only one component. Hospitals still need trained teams, validated equipment, rehabilitation resources, and ongoing medical support.

Precision's commercial partnership with Medtronic is particularly interesting because it provides access to an established medical-device company with experience in neurosurgery, regulation, manufacturing, and distribution.

Process improvements and larger production volumes should reduce some expenses. There is not yet enough public commercial data to estimate how far complete treatment costs will fall.

Approach	Where costs could fall	What remains expensive
Neuralink	Robotic electrode placement	Implantation and long-term servicing
Synchron	Use of existing endovascular procedures	Specialist teams and follow-up
Precision Neuroscience	Integration into neurosurgical workflows	Surgical access and full-system development
BrainGate research	Established decoding methods	Research-intensive clinical support
Medtronic DBS	Mature manufacturing and distribution	Surgery, programming, replacement
Noninvasive EEG	No implantation surgery	Calibration and reliable software
Ultrasound interfaces	Potentially no implanted hardware	Imaging equipment and signal processing
Eye-tracking systems	Established assistive hardware	Accessibility integration and training

Does neurotech have enough brain data to train reliable AI?

Neurotechnology still lacks enough diverse, comparable human neural data to make its best AI models work reliably across patients.

The problem is unusual. Individual neural-recording sessions can produce enormous quantities of data, while the number of implanted patients remains relatively small.

The historical BCI review covering 1998–2023 identified only 67 recipients, with substantial differences in electrode types, medical conditions, and experimental designs.

Precision Neuroscience is trying to address part of this problem by collecting recordings across many patients and surgical locations. In October 2026, research involving its first 70 patients described recordings from more than 100 nervous-system sites, covering functions including movement, speech, and facial expression.

The work was presented as a preprint, so its conclusions still require peer-reviewed scrutiny. Still, the scale is meaningful for a field historically dominated by very small studies.

There are also promising efforts to train neural models on large quantities of unlabeled recordings. These could reduce the amount of individual calibration required for new users.

The remaining difficulty is getting models trained on one person's neural activity to work consistently for another person whose anatomy, condition, or recording configuration differs.

Could brain-data privacy become neurotech's biggest ethical problem?

Brain-data privacy is already one of neurotechnology's most serious ethical problems, especially as neural monitoring moves beyond hospitals into workplaces and consumer products.

Neural recordings can contain information associated with movement, attention, sleep, health conditions, and responses to stimuli. Some of these measurements can support useful applications, but they can also expose sensitive information when combined with other data.

In November 2025, UNESCO adopted its Recommendation on the Ethics of Neurotechnology. The framework addresses mental privacy, autonomy, informed consent, and the risks of using neural information to influence or discriminate against individuals.

A more recent United Nations warning has also highlighted potential misuse of neurotechnology in criminal justice and other settings where people may have limited freedom to refuse monitoring.

Cybersecurity adds another layer. Connected implants can involve wireless communication, remote updates, and sensitive medical information. The FDA's medical-device cybersecurity guidance, updated in February 2026, addresses vulnerability management and secure device maintenance.

We should avoid exaggerating current capabilities. Today's consumer EEG headsets cannot freely read someone's private thoughts, and there is no evidence of widespread attacks against implanted BCIs.

The real concern is that neural information could be collected, analyzed, retained, or reused in ways people never knowingly agreed to.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

What happens if a neurotech startup shuts down after implanting patients?

A neurotech startup shutting down can leave patients dependent on medical hardware that no longer has reliable technical support.

The U.S. GAO raised this concern in its December 2024 assessment, noting that some implanted-BCI research participants had previously lost access to continued support or undergone device removal after research funding ended.

This problem goes beyond bankruptcy. A company might discontinue an older implant, change its software platform, stop manufacturing replacement components, or sell its technology to another business.

For someone relying on an implant to communicate, an interruption could have serious consequences.

Neurotechnology companies therefore need continuity plans covering software access, compatible hardware, clinical responsibilities, data portability, and device removal when necessary.

The growing role of established medical-device partners could help. Precision's relationship with Medtronic, for instance, provides a route toward existing clinical and service infrastructure. It does not guarantee lifelong device support.

The question deserves far more attention because a patient could remain dependent on a functioning implant long after the original startup has changed ownership or disappeared.

Are consumer neurotech companies promising more than their devices can deliver?

Consumer neurotechnology frequently makes claims about concentration, cognitive performance, and emotional states that go beyond what brain recordings can establish reliably.

Companies such as EMOTIV, Muse, and Neurable have developed products that record or analyze signals associated with brain activity. Some target research and professional applications, while others focus on wellness and everyday use.

These products can provide useful measurements, particularly under controlled conditions. However, EEG signals are affected by eye movement, muscle activity, electrode positioning, fatigue, and environmental noise.

A change in an EEG-derived attention score therefore does not necessarily prove that someone's cognitive performance improved.

Neurable's consumer headphone products illustrate how neural sensing is moving into ordinary electronics. The opportunity is interesting, but commercial adoption and scientific validation should be assessed separately.

This becomes especially important in workplaces and schools. An employer might be tempted to use brain-monitoring scores to evaluate productivity, even when those measurements were never validated for judging employee performance.

The industry's credibility will depend partly on whether consumer companies make claims that independent studies can reproduce.

Is neurotech attracting money faster than it is attracting patients?

Neurotech investment is growing much faster than permanent brain-computer interface adoption, making commercial expectations a serious concern.

The Financial Times recently reported that venture funding for neurotechnology increased from approximately $2.3 billion in 2024 to $4.8 billion in 2025. That represents an increase of roughly 109%, although funding totals depend on which companies and financing categories are included.

More recent brain-computer interface funding data show that activity is spreading beyond a few large companies.

A New Market Pitch analysis of disclosed and identified BCI financings counted 51 deals across 41 companies during the latest 12-month period, compared with 15 deals across 15 companies in the preceding period. Quantified funding rose from at least $1.10 billion to at least $1.67 billion.

Excluding financings above $50 million, the recorded total approximately doubled from $245.8 million to $496.1 million. Investors are increasingly backing smaller BCI companies rather than concentrating all their attention on a few major funding rounds.

Precision Neuroscience's $250 million Series D in September 2026 shows that large financings remain important too.

These numbers demonstrate growing investor interest, while the clinical market remains at a much earlier stage. Most permanent communication BCIs are still experimental, and investment activity alone tells us little about recurring revenue or reimbursement.

The strongest commercial opportunities may initially come from established therapeutic treatments, surgical applications, and specialist monitoring rather than mass-market brain implants.

If you want more recent data on this point, see the latest figures in our Neurotech report ↓.

Is neurotechnology becoming a treatment only wealthy patients can access?

Neurotechnology could deepen existing healthcare inequalities because advanced neurological treatments depend on specialists and hospitals that are already distributed very unevenly.

According to the World Health Organization, more than 80% of neurological deaths and health loss occur in low- and middle-income countries. High-income countries can have up to 70 times more neurological professionals per 100,000 people.

The WHO's 2025 Global Status Report on Neurology also found that fewer than one-third of countries had a national policy addressing neurological disorders.

Advanced neurotechnology often requires specialist diagnosis, surgical implantation, programming, rehabilitation, and continued follow-up. Countries already struggling to provide basic neurological services may have difficulty supporting these procedures.

The demand is substantial, but we need to interpret it properly. The estimate of 3.4 billion people affected by nervous-system conditions includes disorders for which implanted BCIs currently offer no established treatment.

For many patients, better access to existing medication, rehabilitation, stroke care, or epilepsy treatment would deliver more immediate benefits than experimental brain implants.

Affordable neurotechnology is an important long-term goal, although improving ordinary neurological care remains the more urgent priority for much of the world.

What would prove that neurotech is finally ready for the mass market?

Neurotechnology will be ready for broader commercial adoption when its devices deliver dependable benefits across many patients, remain useful for years, and can be prescribed and supported through ordinary healthcare systems.

Some neurotechnology has already reached that stage. Deep brain stimulation is an established treatment for selected neurological conditions, and Medtronic's adaptive system extends an existing commercial platform.

Permanent communication BCIs are much earlier in their development.

Precision Neuroscience's growing patient experience and recent funding indicate progress in clinical research and commercialization. Synchron is gathering additional evidence through its INTENT study, while Neuralink continues developing its implanted interface through human trials.

However, the decisive evidence will come from larger studies demonstrating consistent improvements in communication or independence, together with long-term safety and manageable costs.

We should pay particular attention to whether patients can use these systems without intensive research supervision. Independent daily use, stable performance, and predictable medical follow-up would be more convincing than another record-breaking decoding demonstration.

Broader adoption will also depend on reimbursement and healthcare infrastructure, especially for permanent implants.

The first genuinely mature communication BCIs are likely to become specialist medical treatments before anything resembling a consumer product.

Neurotech: what are the biggest challenges now?

The biggest challenges in neurotechnology today are long-term device reliability, proving clinical benefits across larger patient groups, reducing treatment costs, and creating sustainable reimbursement and patient-support systems. Consumer neurotech also faces serious problems with measurement accuracy, privacy, and exaggerated claims.

The science behind brain-computer interfaces has moved ahead of the systems needed to deliver them as routine treatments.

Neuralink, Synchron, Precision Neuroscience, and academic researchers have demonstrated useful neural control and communication capabilities. Medtronic has shown that responsive brain stimulation can become an approved commercial medical technology. Investors are also providing considerably more capital, and new approaches such as ultrasound are attracting attention.

Yet permanent communication implants still lack the scale of clinical evidence, long-term performance records, and established payment pathways needed for widespread adoption.

The next few years should tell us much more about which approaches can work outside research programs. We expect progress to be strongest in applications with clearly defined medical benefits, particularly restoring communication and improving established neurological treatments.

For now, neurotech's biggest challenge is making its existing breakthroughs reliable, affordable, and accessible enough to become part of everyday healthcare.